United Therapeutics Revenue Growth Rates (UTHR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
United Therapeutics Corporation  (NASDAQ: UTHR)
 

UTHR's Revenue Growth by Quarter and Year

United Therapeutics's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/UTHR/growth
https://api.csimarket.com/api/v1/companies/UTHR/fundamentals
https://api.csimarket.com/api/v1/companies/UTHR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
UTHR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 832.50
2nd Quarter June 783.30
1st Quarter March 781.50
FY 2,397.30

UTHRs Annual Revenue
United Therapeutics's Revenue in the fiscal year 2025 $ 3,182.70 millions
United Therapeutics's Revenue in the fiscal year 2024 $ 2,877.40 millions
United Therapeutics's Revenue in the fiscal year 2023 $ 2,327.50 millions
United Therapeutics's Revenue in the fiscal year 2022 $ 1,936.30 millions
United Therapeutics's Revenue in the fiscal year 2021 $ 1,685.50 millions




UTHR Revenue third quarter 2026 Y/Y Growth Comment
United Therapeutics Corporation reported Revenue growth of 4.13% year on year in the third quarter 2026, to $ 832.50 millions, this is lower than United Therapeutics Corporation's recent average Revenue increase of 13.85%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 141 other companies have achieved higher Revenue growth. While United Therapeutics Corporation' s Revenue increase of 4.13% ranks overall at the positon no. 2998 in the third quarter 2026.


UTHR Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 4.13 %
2nd Quarter June -1.92 %
1st Quarter March -1.62 %
FY   -

Financial Statements
United Therapeutics's third quarter 2026 Revenue $ 832.50 millions UTHR's Income Statement
United Therapeutics's third quarter 2025 Revenue $ 799.50 millions Quarterly UTHR's Income Statement


UTHR Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 6.28 %
2nd Quarter June 0.23 %
1st Quarter March -1.1 %
FY (Year on Year)   -


Back to UTHR Growth rate Comparisons >> Back to UTHR Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #142
Healthcare Sector #413
Overall #2998

Revenue Y/Y Growth Statistics
High Average Low
73.4 % 13.85 % -18.43 %
(Jun 30 2011)   (Jun 30 2019)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #142
Healthcare Sector #413
Overall #2998
Revenue Y/Y Growth Statistics
High Average Low
73.4 % 13.85 % -18.43 %
(Jun 30 2011)   (Jun 30 2019)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

United Therapeutics's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
25.13 % 3.38 % -22.52 %
(Sep 30 2010)  


UTHR's III. Quarter Q/Q Revenue Comment
United Therapeutics Corporation achieved in the III. Quarter 2026 above company average sequential Revenue increase of 6.28%, to $ 832.50 millions, from $783.30 millions in the second quarter.
UTHR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 82 other companies have achieved higher Revenue quarter on quarter growth. While United Therapeutics's Revenue growth quarter on quarter, overall rank is 1757.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #83
Healthcare Sector #230
Overall #1757
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #83
Healthcare Sector #230
Overall #1757
Revenue Q/Q Growth Statistics
High Average Low
25.13 % 3.38 % -22.52 %
(Sep 30 2010)  


UTHR's III. Quarter Q/Q Revenue Comment
United Therapeutics Corporation achieved in the III. Quarter 2026 above company average sequential Revenue increase of 6.28%, to $ 832.50 millions, from $783.30 millions in the second quarter.
UTHR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 82 other companies have achieved higher Revenue quarter on quarter growth. While United Therapeutics's Revenue growth quarter on quarter, overall rank is 1757.


United Therapeutics's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 3,154.50
Y / Y Revenue Growth (TTM) 2.49 %
Year on Year Revenue Growth Overall Ranking # 972
Seqeuential Revenue Change (TTM) -0.48 %
Seq. Revenue Growth (TTM) Overall Ranking # 2331


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, United Therapeutics's cumulative twelve months Revenue were $ 3,155 millions, company would post below average annual Revenue growth of -0.48% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the United Therapeutics's Revenue growth from the 783.3% growth in Mar 31 2026.

In the Healthcare sector 186 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 203 to 972.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 187
Overall # 972

Revenue TTM Y/Y Growth Statistics
High Average Low
53.57 %
 12.88 %
-12.25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 336
S&P 500 # 2331
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, United Therapeutics's cumulative twelve months Revenue were $ 3,155 millions, company would post below average annual Revenue growth of -12.25% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the United Therapeutics's Revenue growth from the 783.3% growth in Mar 31 2026.

In the Healthcare sector 186 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 203 to 972.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 187
Overall # 972

Revenue TTM Y/Y Growth Statistics
High Average Low
53.57 %
12.88 %
-12.25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 336
S&P 500 # 2331




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
UTHR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Addus Homecare Corp7.19%$ 7.193 millions
Pacific Biosciences Of California Inc 7.03%$ 7.026 millions
Bristol myers Squibb Company6.93%$ 6.930 millions
Labcorp Holdings Inc 6.92%$ 6.917 millions
Gilead Sciences Inc 6.83%$ 6.835 millions
Arcturus Therapeutics Holdings Inc 6.68%$ 6.682 millions
National Healthcare Corp6.61%$ 6.614 millions
Tenet Healthcare Corp6.47%$ 6.466 millions
Phibro Animal Health Corporation6.32%$ 6.320 millions
Mettler toledo International Inc 6.27%$ 6.273 millions
Agilon Health Inc 5.86%$ 5.864 millions
Johnson and Johnson5.86%$ 5.860 millions
Stoke Therapeutics Inc 5.86%$ 5.860 millions
Genedx Holdings Corp 5.64%$ 5.642 millions
Adma Biologics Inc 5.59%$ 5.595 millions
Innoviva Inc 5.55%$ 5.551 millions
Universal Health Services Inc 5.30%$ 5.297 millions
Acadia Healthcare Company Inc 5.14%$ 5.136 millions
Lumexa Imaging Holdings Inc 5.03%$ 5.032 millions
Bio techne Corp4.75%$ 4.753 millions
Merck and Co Inc 4.68%$ 4.683 millions
Davita Inc 4.62%$ 4.617 millions
Sotera Health Company4.61%$ 4.613 millions
Avantor Inc 4.59%$ 4.588 millions
Icu Medical Inc4.39%$ 4.388 millions
Illumina Inc 4.15%$ 4.151 millions
Agenus Inc4.14%$ 4.144 millions
United Therapeutics Corporation4.13%$ 4.128 millions
Option Care Health Inc 4.09%$ 4.086 millions
Henry Schein Inc 3.95%$ 3.953 millions


About United Therapeutics Revenue Growth Rates (UTHR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: United Therapeutics Corp (CIK 1082554).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001082554-26-000035
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: United Therapeutics Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.